Randy Milby

Chief Executive Officer

 

Randy Milby was appointed Chief Executive Officer in January, 2013. He joined CorMedix in May 2012 as Chief Operating Officer. Previously, Mr. Milby was co-founder and a managing director of WaterStone Bridge, LLC, a healthcare consulting services firm. During his 11 year tenure at DuPont Company, he held several management positions, the most recent as Global Business Director, Applied Biosciences. From 1998 through 1999, Mr. Milby was also a Healthcare Analyst at Goldman Sachs & Company. Mr. Milby received his Pharmacy degree at the University of Kansas and his MBA from Washington University, St. Louis.

 

Antony E. Pfaffle, M.D.  

Chief Scientific Officer and Co-Founder

 

Antony Pfaffle, M.D. has been a director of CorMedix since February 2007, was appointed as interim Chief Scientific Officer effective January 1, 2013, and Chief Scientific Officer in July 2014. Dr. Pfaffle has been Director of Healthcare Research at Bearing Circle Capital, L.P., an investment fund, since May 2007. He is an Advisory Medical Director for ParagonRx, an Inventiv Company specializing in drug and device risk evaluation and mitigation. He was a Managing Director at Paramount BioCapital, Inc. and Senior Vice-President of Business Development at Paramount BioSciences, LLC from December 2005 to May 2007. Dr. Pfaffle was a Principal and Founder of Black Diamond Research, an investment research company, from July 2001 to December 2005. Dr. Pfaffle is an internist who practiced nephrology at New York Hospital-Weill Cornell Medical Center, Lenox Hill Hospital and Memorial Sloan-Kettering Cancer Center. Dr. Pfaffle received his M.D. from New York Medical College.

 

James Altland

Interim Chief Financial Officer

 

Prior to his appointment at Cormedix, Mr. Altland served from February 2007 to May 2014 as Senior Vice President of Finance and Corporate Development of Onconova Therapeutics, Inc., a pharmaceutical company headquartered in Newtown, Pennsylvania. Before joining Onconova, Mr. Altland was a Partner with Tatum, a leading professional and interim services firm headquartered in New York, New York.  Mr. Altland received his B.S. in Accounting in 1971 from the University of Akron.

 

John Ortiz

Vice President, Regulatory Affairs and Quality Assurance

 

John Ortiz, who joined CorMedix in January 2015, has held executive positions in quality assurance/quality control and regulatory affairs at Johnson & Johnson’s domestic and international operations, Janssen Pharmaceutical and Correvio LLC. In these roles, Mr. Ortiz oversaw the design of operations and quality control facilities, acquisition of innovative testing technologies, and quality management systems for pharmaceutical drugs and medical devices compliant with regulatory statutes and guidelines set by the U.S. Food and Drug Administration and EU Pharmaceutical Commission, and international operations including Asia Pacific and Latin America. He has also directed interdisciplinary teams and functions relating to the development of pharmaceutical products in diverse delivery systems, as well as the clinical and post-approval manufacturing and commercial distribution phases. Mr. Ortiz has more than 30 years of experience in the pharmaceutical industry.

 

​